Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
about
Current developments in pharmacological therapeutics for chronic constipationTreatment for constipation: new and old pharmacological strategiesClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic targetResearch and progress on ClC‑2 (Review).Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon.Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.Limited efficacy of α-conopeptides, Vc1.1 and RgIA, to inhibit sensory neuron CaV currentAdvancing treatment options for chronic idiopathic constipation.Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Aqueous cigarette smoke extract induces a voltage-dependent inhibition of CFTR expressed in Xenopus oocytes.Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.The use of non-narcotic pain medication in pediatric gastroenterology.Pharmaceutical Activation or Genetic Absence of ClC-2 Alters Tight Junctions During Experimental Colitis.Identification of the fatty acid activation site on human ClC-2.Cellular mechanism for herbal medicine Junchoto to facilitate intestinal Cl-/water secretion that involves cAMP-dependent activation of CFTR.Recent advances in understanding and managing chronic constipation
P2860
Q27025474-F07EFB4A-9EF1-4E90-AAC5-BFB864C399A6Q27027346-CEABC924-BE87-4A5F-A500-56229AF9F9BBQ28066092-4D0EBB31-BE1B-43C1-8FB7-08CF4081A46BQ33828111-7A14D26D-BACC-4DC0-9071-332EB8FD6CABQ33854983-E14B7BAB-6479-4D6C-BFC7-0E05CDF3D1A5Q34097910-5CE086EB-A642-405A-95DD-8B6B32DD7848Q34478089-F3509609-C144-42BF-B2CA-262308B58DA3Q34522966-0CB4000B-2CAA-493A-B354-197A2211596BQ35735112-3DA005BE-F722-4F76-A17C-5C05060C8B4AQ35858864-3BE6E1CC-FD19-4C1E-8510-9A7BB26296EFQ37491434-FF86ED65-5E22-4E64-AC52-D8DE6F929A78Q37576067-EB7605E8-0959-4620-9845-648452E334CBQ38134412-8B657C6E-281C-42B9-83DF-D98AF85D9281Q38221358-D7BA0EEF-036C-46B4-9863-0F57FE5B562DQ44859490-B8C15876-85EF-499B-9272-A8B7E0CACABAQ50716076-01C9F3E1-1BB9-4C15-8650-2A34D2C4AEC7Q55185820-F95D47EE-960F-4DD6-8BFA-5D0760374723Q58562464-E0A2E83D-A3D0-432E-82DD-330256A75B62
P2860
Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
@ast
Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
@en
type
label
Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
@ast
Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
@en
prefLabel
Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
@ast
Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
@en
P2093
P2860
P1476
Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
@en
P2093
Aurelia R Moran
Kelvin D MacDonald
Yohei Norimatsu
P2860
P304
P356
10.1016/J.BBRC.2012.08.097
P407
P577
2012-08-29T00:00:00Z